TLDR: Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery
- Carlsmed, an AI-enabled personalized surgery Medtech company, secures $52.5M in Series C funding round co-led by B Capital and U.S. Venture Partners
- The funds will be used to accelerate the commercialization of the aprevo ® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo ® for cervical fusions
Carlsmed, an AI-enabled personalized surgery Medtech company, has announced a successful $52.5 million Series C funding round co-led by B Capital and U.S. Venture Partners. The funding will be utilized to advance the commercialization of the aprevo ® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo ® for cervical fusions, set to launch in 2025. The company’s CEO, Mike Cordonnier, expressed their commitment to enhancing patient outcomes through personalized surgery, with significant clinical publications endorsing the effectiveness of aprevo ® patient-specific implants. The FDA has granted Breakthrough Device designation to Carlsmed for its aprevo ® lumbar and cervical patient-specific interbody fusion devices, showcasing the company’s innovation in the field of spine surgery. With a focus on transforming spine surgery through AI-enabled technology, Carlsmed looks set to redefine the standard of care in the industry.
